Imaging Diagnostic Systems (IDS) has received approval from the Ministry of Health in Kuwait to market and sell its CTLM 3D laser breast imaging system in the country. Mareen Group will be the exclusive distributor of CTLM in Kuwait. A study published in the March 2013 edition of Clinical Imaging highlighted that CTLM could distinguish benign lesions from malignant lesions and is not affected by breast density.
IDS is the developer of CTLM, an optical breast imaging device. Optical mammography is a diffuse optical tomography technique that aims at detecting breast cancer. CTLM employs patented continuous wave laser technology and computed algorithms to create 3D images of the breast. The procedure is non-invasive, painless, does not expose the patient to ionising radiation or painful breast compression and also does not involve use of contrasting agents. CTLM has received certification and licences to sell internationally through the following approvals: CE marking, Health Canada, Chinese State FDA and US FDA export certification. Marketing clearances are pending in Mexico and Russia.